GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (XTAE:BWAY) » Definitions » Loans Receivable

BrainsWay (XTAE:BWAY) Loans Receivable : ₪0.0 Mil (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is BrainsWay Loans Receivable?

BrainsWay's Loans Receivable for the quarter that ended in Sep. 2024 was ₪0.0 Mil.


BrainsWay Loans Receivable Historical Data

The historical data trend for BrainsWay's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Loans Receivable Chart

BrainsWay Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BrainsWay Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BrainsWay Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


BrainsWay Loans Receivable Related Terms

Thank you for viewing the detailed overview of BrainsWay's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.